Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

62.59 +0.65 (+1.05%)
Streaming Delayed Price Updated: 12:48 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
Via Benzinga
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month. 
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
15 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a  
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue. 
Via The Motley Fool
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The innovation-fueled Nasdaq Composite remains 13% below its all-time high, which means bargains can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
With the growth-driven Nasdaq Composite still 14% below its record-closing high, deals abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the  
Via Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers 
Via InvestorPlace
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.